HIV PEP using a 2-drug regimen

If a 2-drug regimen is indicated for HIV postexposure prophylaxis in adults and children 16 years or older, suitable regimens include:

1tenofovir disoproxil fumarate+emtricitabine 300+200 mg orally, daily for 4 weeks. For dosage adjustment in adults with kidney impairment, see tenofovir disoproxil fumarate+emtricitabine dosage adjustment tenofovir disoproxil fumarate + emtricitabine tenofovir disoproxil fumarate+emtricitabine tenofovir disoproxil fumarate+emtricitabine

OR

1tenofovir disoproxil maleate+emtricitabine 300+200 mg orally, daily for 4 weeks. For dosage adjustment in adults with kidney impairment, see tenofovir disoproxil maleate+emtricitabine dosage adjustment tenofovir disoproxil maleate+emtricitabine (Tenofovir Disoproxil Emtricitabine Mylan 300/200) tenofovir disoproxil maleate+emtricitabine tenofovir disoproxil maleate+emtricitabine

OR

1tenofovir disoproxil phosphate+emtricitabine 291+200 mg orally, daily for 4 weeks. For dosage adjustment in adults with kidney impairment, see tenofovir disoproxil phosphate+emtricitabine dosage adjustment tenofovir disoproxil phosphate+emtricitabine (Tenofovir EMT GH) tenofovir disoproxil phosphate+emtricitabine tenofovir disoproxil phosphate+emtricitabine

OR

1tenofovir disoproxil succinate+emtricitabine 301+200 mg orally, daily for 4 weeks. For dosage adjustment in adults with kidney impairment, see tenofovir disoproxil succinate+emtricitabine dosage adjustment tenofovir disoproxil succinate+emtricitabine tenofovir disoproxil succinate+emtricitabine tenofovir disoproxil succinate+emtricitabine

OR

2lamivudine+zidovudine 150+300 mg orally, 12-hourly for 4 weeks. For dosage adjustment in adults with kidney impairment, see lamivudine+zidovudine dosage adjustment. lamivudine + zidovudine lamivudine+zidovudine (Combivir) lamivudine+zidovudine (Combivir)

There are many tenofovir disoproxil+emtricitabine fixed-dose combination products available in Australia. The formulations included above are bioequivalent.

If there is exposure to drug-resistant HIV or if adverse effects of the above regimens limit their use, seek expert advice.